基質金屬蛋白酶-7的基因型與中台灣民眾罹患膀胱癌風險的關聯性
廖丞晞1,2,3,4、吳錫金5 、張文馨2,3、胡佩欣6 、蔡佳紋2,3、包大靝2,3,4
1國軍台中總醫院泌尿外科; 2中國醫藥大學臨床醫學研究所; 3Terry Fox癌症研究室;
4國防醫學院臨床醫學研究所; 5中國醫藥大學附設醫院泌尿外科; 6彰化基督教醫院眼科部
The Association of Matrix Metalloproteinase-7 Genotypes with the Risk of Bladder Cancer in mid-Taiwanese People
Cheng-Hsi Liao1,2,3,4, Wen-Shin Chang2,3, Chia-Wen Tsai2,3, Hsi-Chin Wu5, Pei-Shin Hu3,6, and Da-Tian Bau2,3
1Division of Urology, Department of Surgery, Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.; 2Graduate Institute of Biomedical Science, China Medical University, Taichung, Taiwan, R.O.C.; 3Terry Fox Cancer Research Laboratory; 4Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, R.O.C.; 5Department of Urology, China Medical University Hospital, Taichung, Taiwan, R.O.C.; 6Department of Ophthalmology, Changhua Christian hospital, Changhua, Taiwan, R.O.C.
Purpose: The breakage of matrix metalloproteinases (MMPs) has been reported to be one of the mechanisms required for tumor invasion, and the expression of MMP-7 in serum is correlated with poor prognosis of urinary bladder cancer patients. However, the role of the MMP-7 genotypes has been seldom examined among bladder cancer patients. Therefore, this study aimed at examining the promoter polymorphic MMP-7 genotypesA-181G and C-153T among Taiwanese bladder cancer patients and evaluate the contribution of the genotypic variants of MMP-7 to bladder cancer risk in Taiwan.
Materials and Methods: Three hundred and seventy-five bladder cancer patients and the same number of gender- and age-matched healthy controls were genotyped for A-181G and C-153T in the promoter of MMP-7 via polymerase chain reaction-restriction fragment length polymorphism methodology.
Results: The frequencies of AA, AG and GG atA-181G of the promoter of MMP-7 were 89.1, 8.8 and 2.1% in the bladder cancer patient group and 87.5, 10.9 and 1.6% in the matched healthy control group, respectively (p for trend=0.5475). There was no polymorphic genotype for MMP-7 C-153T among the Taiwanese population. The comparisons in allelic frequency distribution also support the findings that the G allele may not be the determinant allele for bladder cancer in Taiwan. In addition, the results showed that there is no significant association of the bladder risk with the MMP-7 A-181G genotype, even after adjustment for the possible confounding factors. Furthermore, there is no interaction of the genotypes of MMP-7 with age, gender, smoking and alcohol consumption on bladder cancer risk.
Conclusion: The results of this study suggest that the two MMP-7 polymorphisms, A-181G and C-153T, do not play a major role in determining personal susceptibility to bladder cancer in Taiwan.